RxDoctor Payments Data

Barry Welch, MD

Ophthalmology · Cody, WYNPI 1437157484

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.8% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 72.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $155 and has fallen 59.1% since, to $63 in 2025.

$385in general payments, 2019–2025

Across 14 payments — averaging $27.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$281
  • Rxsight Inc$37
  • AbbVie$28
  • LKC Technologies, Inc.$25
  • Harrow Eye, LLC$15

What the payments were for

  • Travel & lodging$123%
  • Food & beverage$37397%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon9$281
Rxsight Inc1$37
AbbVie2$28
LKC Technologies, Inc.1$25
Harrow Eye, LLC1$15

How this compares

Too few ophthalmology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$515,893
Medicare patients
1,173
Services billed
6,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine50$61,226
CombiganBrimonidine Tartrate/Timolol50$21,356
LumiganBimatoprost37$21,327
RocklatanNetarsudil Mesylat/Latanoprost17$9,024
Brimonidine Tartrate87$4,959
Latanoprost276$3,624
RhopressaNetarsudil Mesylate11$3,389
Timolol Maleate87$3,180
Loteprednol Etabonate11$1,844
Brinzolamide12$1,639
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$1,511
Dorzolamide Hcl61$1,313
Prednisolone Acetate20$756
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat50$637
ErythromycinErythromycin Base29$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$28$103,909137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few ophthalmology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other ophthalmology in Cody

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →